Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02879305 · ClinicalTrials.gov registry record · Phase 3
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,964
- Enrollment target
NCT02879305: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT02879305 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,964 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (284% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02879305, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,964 participants
- Enrollment target
Study Summary
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
Primary Outcome
Time to MACE defined as the time to first occurrence of Clinical Events Committee (CEC) adjudicated MACE (composite of all-cause mortality, non-fatal myocardial infarction \[MI\] and non-fatal stroke) was analyzed using a Cox proportional hazards regression model with treatment group, dialysis type and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) plus (+) 1. The incidence rate per 100 person years calculated as (100 multiplied by \[\*\]
Interventions
- DRUG Placebo
- DRUG Daprodustat
- DRUG rhEPO
- DRUG Iron therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,964 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2020-11-09 |
| Phase | Phase 3 |
What the finished NCT02879305 record still lists
NCT02879305 is an interventional study that assigns participants to a tested intervention. Its 2,964 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (284% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02879305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02879305 about?
NCT02879305 is a clinical study titled "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)". The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
What is the current status of trial NCT02879305?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,964 participants. The study started on 2016-09-28. Estimated completion is 2020-11-09.
What interventions are being tested in trial NCT02879305?
The interventions under investigation include: Placebo (DRUG), Daprodustat (DRUG), rhEPO (DRUG), Iron therapy (DRUG).
Who is sponsoring clinical trial NCT02879305?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02879305's enrollment target sits among peer trials
2,964 80th of 2000 higher than 1,921 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03331380 · 2,950 participants · NA
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System
- NCT05849961 · 2,946 participants
Exactech Hip Systems Post-Market Clinical Follow-up (PMCF)
- NCT05297734 · 2,996 participants · NA
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- NCT03860883 · 2,998 participants · NA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI